These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 2447718)

  • 41. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
    Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
    Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
    Hecht JL; Pinkus JL; Pinkus GS
    Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach.
    Battifora H; Kopinski MI
    Cancer; 1985 Apr; 55(8):1679-85. PubMed ID: 2579718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunohistochemical staining in malignant mesotheliomas.
    Strickler JG; Herndier BG; Rouse RV
    Am J Clin Pathol; 1987 Nov; 88(5):610-4. PubMed ID: 2445194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative ultrastructural study of nuclei from exfoliated benign and malignant mesothelial cells and metastatic adenocarcinoma cells.
    Dardick I; Butler EB; Dardick AM
    Acta Cytol; 1986; 30(4):379-84. PubMed ID: 3461648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases.
    Chu PG; Weiss LM
    Mod Pathol; 2002 Jan; 15(1):6-10. PubMed ID: 11796835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
    Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation.
    Leong AS; Stevens MW; Mukherjee TM
    Semin Diagn Pathol; 1992 May; 9(2):141-50. PubMed ID: 1609156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long microvilli of mesothelioma are conspicuous in pleural effusions processed by Ultrafast Papanicolaou stain.
    Yang GC
    Cancer; 2003 Feb; 99(1):17-22. PubMed ID: 12589641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Keratins in malignant mesotheliomas and pleural adenocarcinomas: comparative immunohistochemical analysis with polyclonal and monoclonal antibodies.
    Bejui-Thivolet F; Patricot LM; Vauzelle JL; Viac J
    Pathol Res Pract; 1984 Sep; 179(1):67-73. PubMed ID: 6209691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
    O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
    Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunoperoxidase staining of malignant cells in pleural effusions.
    Pastormerlo M
    Pathologica; 1990; 82(1080):421-5. PubMed ID: 2284143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
    Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
    Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of PAS-diastase and carcinoembryonic antigen staining in the differential diagnosis of malignant mesothelioma and papillary serous carcinoma of the ovary.
    Silcocks PB; Herbert A; Wright DH
    J Pathol; 1986 Jun; 149(2):133-41. PubMed ID: 2426430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HMB-45 detection in adenocarcinomas.
    Hancock C; Allen BC; Herrera GA
    Arch Pathol Lab Med; 1991 Sep; 115(9):886-90. PubMed ID: 1718237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
    Churg A
    Am J Surg Pathol; 1985 May; 9(5):360-5. PubMed ID: 2418692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Solitary (localized) fibrous mesothelioma: evidence against mesothelial cell origin.
    Dervan PA; Tobin B; O'Connor M
    Histopathology; 1986 Aug; 10(8):867-75. PubMed ID: 2428726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Immunohistochemistry of the prostate and prostate carcinomas].
    Wernert N
    Veroff Pathol; 1991; 135():1-163. PubMed ID: 2038892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.